Pornchai Tirakitsoontorn

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8

Muscle Size and Cardiorespiratory Response to Exercise in Cystic Fibrosis

Chuanpit Moser, Pornchai Tirakitsoontorn, Eliezer Nussbaum et al. · American Journal of Respiratory and Critical Care Medicine · 2000 · 115 citations · Full text

Education, Physiology, Exercise Physiology +16

Fitness, Acute Exercise, and Anabolic and Catabolic Mediators in Cystic Fibrosis

Pornchai Tirakitsoontorn, Eliezer Nussbaum, Chuanpit Moser et al. · American Journal of Respiratory and Critical Care Medicine · 2001 · 88 citations · Full text

Education, Immunology, Physiology +14

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

Jordana E. Hoppe, Ajay S. Kasi, Jessica E. Pittman et al. · The Lancet Respiratory Medicine · 2025 · 47 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Recognition of the peripheral airway impairment phenotype in children with well-controlled asthma

Pornchai Tirakitsoontorn, Maisie Crookes, William Fregeau et al. · Annals of Allergy Asthma & Immunology · 2018 · 38 citations

Medicine, Child Health, Pediatrics +13